INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA
Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on efficacy and safety outcomes that may have been undet...
Guardado en:
| Autores principales: | , , , , , , , , , , , |
|---|---|
| Formato: | article |
| Lenguaje: | EN |
| Publicado: |
Elsevier
2021
|
| Materias: | |
| Acceso en línea: | https://doaj.org/article/50e75989ab3e4389a9bb0fcf5b02f584 |
| Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
| id |
oai:doaj.org-article:50e75989ab3e4389a9bb0fcf5b02f584 |
|---|---|
| record_format |
dspace |
| spelling |
oai:doaj.org-article:50e75989ab3e4389a9bb0fcf5b02f5842021-11-10T04:36:41ZINTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA2531-137910.1016/j.htct.2021.10.1047https://doaj.org/article/50e75989ab3e4389a9bb0fcf5b02f5842021-11-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S2531137921011949https://doaj.org/toc/2531-1379Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on efficacy and safety outcomes that may have been undetected in the individual trials. Methodology: In both trials, patients with an acute episode of aTTP were randomized to receive CPLZ or placebo (PBO) in addition to therapeutic plasma exchange (TPE) and immunosuppression. All randomized patients from both studies were included in the integrated efficacy analyses (CPLZ: n=108; PBO: n=112), and those who received at least 1 dose of the study drug were included in the safety analyses (CPLZ: n=106; PBO: n=110). Results: CPLZ significantly reduced mortality (0 vs 4 deaths; P<0.05) and refractory TTP (0 vs 8 events; P<0.05) versus PBO and improved time to platelet count response (hazard ratio, 1.65; P<0.001). CPLZ also reduced the composite endpoint of TTP-related death, exacerbation, or any treatment-emergent major thromboembolic event during the treatment period (13.0% vs 47.3%; P<0.001) and median number of TPE days (5.0 vs 7.5 days) versus PBO. Mild mucocutaneous bleeding was the main safety finding for CPLZ. Conclusion: This integrated analysis provided new evidence that CPLZ prevents mortality and refractory disease in aTTP and reinforced the individual trial efficacy and safety findings. No new safety signals were identified forFlora PeyvandiSpero CatalandMarie ScullyPaul CoppoPaul KnoeblJohanna A. Kremer HovingaAra MetjianJavier de la RubiaKaterina PavenskiJessica Minkue Mi EdouFilip CallewaertHilde De WinterElsevierarticleDiseases of the blood and blood-forming organsRC633-647.5ENHematology, Transfusion and Cell Therapy, Vol 43, Iss , Pp S46-S47 (2021) |
| institution |
DOAJ |
| collection |
DOAJ |
| language |
EN |
| topic |
Diseases of the blood and blood-forming organs RC633-647.5 |
| spellingShingle |
Diseases of the blood and blood-forming organs RC633-647.5 Flora Peyvandi Spero Cataland Marie Scully Paul Coppo Paul Knoebl Johanna A. Kremer Hovinga Ara Metjian Javier de la Rubia Katerina Pavenski Jessica Minkue Mi Edou Filip Callewaert Hilde De Winter INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA |
| description |
Objective: An integrated analysis based on the Phase 2 TITAN (NCT01151423) and Phase 3 HERCULES (NCT02553317) studies with caplacizumab (CPLZ) in acquired thrombotic thrombocytopenic purpura (aTTP) was performed to assess treatment differences on efficacy and safety outcomes that may have been undetected in the individual trials. Methodology: In both trials, patients with an acute episode of aTTP were randomized to receive CPLZ or placebo (PBO) in addition to therapeutic plasma exchange (TPE) and immunosuppression. All randomized patients from both studies were included in the integrated efficacy analyses (CPLZ: n=108; PBO: n=112), and those who received at least 1 dose of the study drug were included in the safety analyses (CPLZ: n=106; PBO: n=110). Results: CPLZ significantly reduced mortality (0 vs 4 deaths; P<0.05) and refractory TTP (0 vs 8 events; P<0.05) versus PBO and improved time to platelet count response (hazard ratio, 1.65; P<0.001). CPLZ also reduced the composite endpoint of TTP-related death, exacerbation, or any treatment-emergent major thromboembolic event during the treatment period (13.0% vs 47.3%; P<0.001) and median number of TPE days (5.0 vs 7.5 days) versus PBO. Mild mucocutaneous bleeding was the main safety finding for CPLZ. Conclusion: This integrated analysis provided new evidence that CPLZ prevents mortality and refractory disease in aTTP and reinforced the individual trial efficacy and safety findings. No new safety signals were identified for |
| format |
article |
| author |
Flora Peyvandi Spero Cataland Marie Scully Paul Coppo Paul Knoebl Johanna A. Kremer Hovinga Ara Metjian Javier de la Rubia Katerina Pavenski Jessica Minkue Mi Edou Filip Callewaert Hilde De Winter |
| author_facet |
Flora Peyvandi Spero Cataland Marie Scully Paul Coppo Paul Knoebl Johanna A. Kremer Hovinga Ara Metjian Javier de la Rubia Katerina Pavenski Jessica Minkue Mi Edou Filip Callewaert Hilde De Winter |
| author_sort |
Flora Peyvandi |
| title |
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA |
| title_short |
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA |
| title_full |
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA |
| title_fullStr |
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA |
| title_full_unstemmed |
INTEGRATED EFFICACY RESULTS FROM THE PHASE 2 AND PHASE 3 STUDIES WITH CAPLACIZUMAB IN PATIENTS WITH ACQUIRED THROMBOTIC THROMBOCYTOPENIC PURPURA |
| title_sort |
integrated efficacy results from the phase 2 and phase 3 studies with caplacizumab in patients with acquired thrombotic thrombocytopenic purpura |
| publisher |
Elsevier |
| publishDate |
2021 |
| url |
https://doaj.org/article/50e75989ab3e4389a9bb0fcf5b02f584 |
| work_keys_str_mv |
AT florapeyvandi integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT sperocataland integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT mariescully integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT paulcoppo integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT paulknoebl integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT johannaakremerhovinga integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT arametjian integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT javierdelarubia integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT katerinapavenski integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT jessicaminkuemiedou integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT filipcallewaert integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura AT hildedewinter integratedefficacyresultsfromthephase2andphase3studieswithcaplacizumabinpatientswithacquiredthromboticthrombocytopenicpurpura |
| _version_ |
1718440553786376192 |